$16.93
2.76%
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US55083R1041
Symbol
LYEL

Lyell Immunopharma Inc Stock price

$16.93
+0.07 0.42% 1M
+9.13 117.05% 6M
+4.13 32.27% YTD
-5.07 23.05% 1Y
-77.07 81.99% 3Y
-320.87 94.99% 5Y
-320.87 94.99% 10Y
-320.87 94.99% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
-0.48 2.76%
ISIN
US55083R1041
Symbol
LYEL
Industry

Key metrics

Basic
Market capitalization
$359.2m
Enterprise Value
$82.4m
Net debt
positive
Cash
$276.8m
Shares outstanding
14.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5,987.1 | 33,540.6
EV/Sales
1,373.9 | 7,696.5
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
78.0%
Return on Equity
-89.6%
ROCE
-61.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$60.0k | $10.7k
EBITDA
$-198.9m | $-200.6m
EBIT
$-215.2m | $-208.7m
Net Income
$-331.4m | $-173.6m
Free Cash Flow
$-203.3m
Growth (TTM | estimate)
Revenue
0.0% | -82.2%
EBITDA
3.2% | 0.0%
EBIT
4.6% | 5.3%
Net Income
-57.6% | 49.4%
Free Cash Flow
-27.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-331,485.0% | -1,872,638.1%
EBIT
-358,621.7%
Net
-552,328.3% | -1,620,943.0%
Free Cash Flow
-338,905.0%
More
EPS
$-22.4
FCF per Share
$-13.7
Short interest
1.1%
Employees
300
Rev per Employee
$0.0
Show more

Is Lyell Immunopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Lyell Immunopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Lyell Immunopharma Inc forecast:

1x Buy
13%
3x Hold
38%
4x Sell
50%

Analyst Opinions

8 Analysts have issued a Lyell Immunopharma Inc forecast:

Buy
13%
Hold
38%
Sell
50%

Financial data from Lyell Immunopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.06 0.06
0% 0%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 50 50
8% 8%
83,533%
- Research and Development Expense 168 168
5% 5%
280,733%
-199 -199
3% 3%
-331,483%
- Depreciation and Amortization 16 16
19% 19%
27,133%
EBIT (Operating Income) EBIT -215 -215
5% 5%
-358,622%
Net Profit -331 -331
58% 58%
-552,333%

In millions USD.

Don't miss a Thing! We will send you all news about Lyell Immunopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lyell Immunopharma Inc Stock News

Neutral
GlobeNewsWire
5 days ago
Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer in an ongoing U.S. Phase 1 clinical trial Received RMAT designation from the U.S. FDA for ron...
Neutral
GlobeNewsWire
7 days ago
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trial LYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer cel...
Neutral
GlobeNewsWire
14 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL...
More Lyell Immunopharma Inc News

Company Profile

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Lynn Seely
Employees 300
Founded 2018
Website lyell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today